Finance

Lists
PVLA:NASDAQ
Palvella Therapeutics Inc
$152.48
-0.46%
(-0.70) 1D
$153.10
+0.41% (+0.62)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PVLA...
Open
$153.00
High
$156.70
Low
$149.81
Mkt. cap
2.23B
Avg. vol.
267.18K
Volume
241.73K
52-wk high
$179.95
52-wk low
$72.22
EPS
-$5.49
Beta
-0.21
Shares outstanding
14.62M
No. of employees
29
Open
$153.00
High
$156.70
Low
$149.81
Mkt. cap
2.23B
Avg. vol.
267.18K
Volume
241.73K
52-wk high
$179.95
52-wk low
$72.22
EPS
-$5.49
Beta
-0.21
Shares outstanding
14.62M
No. of employees
29
News stories
From web sources and news partners
About Palvella Therapeutics Inc
CEO-
Employees29
Founded-
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitepalvellatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to PVLA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PVLA in the last 3 months.
Highest
Current $152.48
$246.00 (+61.33%)
Average
$227.73 (+49.35%)
Lowest
$207.00 (+35.76%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Reiterated
$243.00
+59.4%
11/09/2026
Ryan Deschner
Raymond James
Buy
Maintained
$230.00
+50.8%
11/06/2026
Danielle Brill
Truist Financial
Buy
Maintained
$207.00
+35.8%
11/06/2026
Trevor Allred
Oppenheimer
Buy
Reiterated
$232.00
+52.2%
11/06/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$230.00
+50.8%
11/06/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$215.00
+41%
11/05/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$246.00
+61.3%
11/06/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$232.00
+52.2%
10/29/2026
Alethia Young
William Blair
Buy
Maintained
-
-
10/28/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$210.00
+37.7%
10/21/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$220.00
+44.3%
10/20/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$246.00
+61.3%
10/20/2026
Unknown Analyst
William Blair
Buy
Initiated
$266.00
+74.4%
10/15/2026
Sharon Zackfia
William Blair
Buy
Initiated
$266.00
+74.4%
10/15/2026
Gautam Chukka
Chardan Capital
Buy
Maintained
$240.00
+57.4%
09/21/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$236.00
+54.8%
08/05/2026
Ritu Baral
TD Cowen
Buy
Maintained
$267.00
+75.1%
08/04/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$250.00
+64%
06/24/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$240.00
+57.4%
05/20/2026
Sudan Loganathan
Stephens
Buy
Initiated
$220.00
+44.3%
05/11/2026
Catherine Novack
JonesTrading
Buy
Maintained
$209.00
+37.1%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.12M
9.33M
12.47M
10.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.18M
5.52M
8.93M
11.90M
Operating expense
11.30M
14.86M
21.40M
22.73M
Total operating expenses
11.30M
14.86M
21.40M
22.73M
Operating income
-11.30M
-14.86M
-21.40M
-22.73M
Other non operating income
-191.00K
54.00K
-122.00K
-1.65M
EBT including unusual items
-12.71M
-15.77M
-21.87M
-24.64M
EBT excluding unusual items
-12.71M
-15.77M
-21.87M
-24.64M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.71M
-15.77M
-21.87M
-24.64M
Net profit margin
-
-
-
-
Earnings per share
-1.08
-1.20
-1.52
-1.70
Interest and investment income
520.00K
1.07M
1.96M
2.55M
Interest expense
-1.74M
-2.04M
-2.31M
-2.81M
Net interest expenses
-1.22M
-966.00K
-343.00K
-263.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps